4
Changes in Ownership
Enliven Therapeutics, Inc. Filed Acc 0001415889-24-020475
CHIEF FINANCIAL OFFICER sold 5,250 shares at an average $26.68 ($140,052)
- CHIEF FINANCIAL OFFICER acquired 5,250 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Hohl Benjamin · CHIEF FINANCIAL OFFICER
Table I: Non-derivative
3 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2024-07-29 | Exercise or conversion : show line 1 in the form 10b5-1 | +5,250 | $2.48 | $13,020 | 5,250 | D |
| 2024-07-29 | Sale : show line 2 in the form 10b5-1 | −5,189 | $26.67 | $138,378 | 61 | D |
| 2024-07-29 | Sale : show line 3 in the form 10b5-1 | −61 | $27.44 | $1,674 | 0 | D |
| Open-market sales · 5,250 sh · avg $26.68 · $140,052 | ||||||
Table II: Derivative
1 line| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2024-07-29 | Exercise or conversion : show line 4 in the form 10b5-1 Stock Option (right to buy) | −5,250 | 204,370 | D |
Loading xslF345X05/form4-07312024_110716.xml…